Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal

Jennifer D Cohen1,2, Matthew Labenski1,2, Nicholas J Mastrandrea1,2

  • 1Southwest Environmental Health Sciences Center, College of Pharmacy, The University of Arizona, Tucson, Arizona.

Molecular Carcinogenesis
|September 3, 2015
PubMed

Insights

Increased B-Raf activity is linked to cancer. This study investigated B-Raf alterations in tuberous sclerosis-2 related kidney cancer, identifying splice variants and phosphorylation sites that may drive tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Increased B-Raf kinase activity is implicated in approximately 7% of human cancers.
  • Tuberous sclerosis-2 (Tsc-2) gene mutations are associated with renal cell carcinoma (RCC).
  • Nephrocarcinogen treatment of Eker rats leads to Tsc-2 loss and altered Raf kinase signaling.

Purpose of the Study:

  • To investigate the transcriptional and post-translational modifications of B-Raf in Tsc-2-deficient renal cancer models.
  • To identify B-Raf alterations contributing to tuberous sclerosis-associated RCC.

Main Methods:

  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) for identifying B-Raf phosphorylation.
  • MicroRotofor liquid-phase isoelectric focusing to analyze B-Raf post-translational modifications.
  • Kinase domain amplification, sequencing, and splice variant analysis in rat models and cell lines.

Main Results:

  • Constitutive phosphorylation of B-Raf at S345 and S483 was identified in Tsc-2-null renal cells (QTRRE).
  • Four distinct B-Raf fractions with varying post-translational modifications were found.
  • Three B-Raf splice variants within the kinase domain were identified; no point mutations were detected. Sorafenib treatment decreased B-Raf/Raf-1/14-3-3 complex formation and p-ERK levels.

Conclusions:

  • B-Raf splice variants and specific phosphorylation sites are present in Tsc-2-deficient renal tumors.
  • These molecular alterations in B-Raf may play a role in the pathogenesis of tuberous sclerosis-associated RCC.
  • Targeting B-Raf signaling could be a potential therapeutic strategy.

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.0K